Cyclic adenosine monophosphate (cAMP), which accumulates in tumor tissues, inhibits CD4+ and CD8+ T-cell responses and macrophage activation, and enhances the Treg response by binding to adenosine A2A receptors [27]. This evidence concerns the gene CD8A and neoplasm.